Send to

Choose Destination
N Engl J Med. 2012 Sep 27;367(13):1187-97. Epub 2012 Aug 15.

Increased survival with enzalutamide in prostate cancer after chemotherapy.

Collaborators (144)

Alasino C, Bella S, Carraro S, Geist M, Abdi E, Begbie S, Briscoe K, Davis I, Dowling A, Ganju V, Gurney H, Hovey E, Ng S, Nottage M, Rosenthal M, Stockler M, Tan T, Wong S, Young R, Krainer M, Loidl W, Machiels J, Mebis J, Renard V, Dumez H, Van Aelst F, Werbrouck P, Ellard S, Joshua A, Karakiewicz P, Lacombe L, Lattouf JB, Michels J, Mukherjee S, Ruether D, Venner P, Winquist E, Wood L, Aren O, Gonzalez P, Pastor P, Baumgaertner I, Beuzeboc P, Bompas E, Boyle H, Colombel M, Delva R, Eymard J, Gravis G, Guillot A, Houédé N, Joly F, Kaphan R, Loriot Y, Oudard S, Priou F, Tartas S, Theodore C, Tourani JM, Voog E, Bögemann M, Hadaschik B, Hammerer P, Heidenreich A, Holzer W, Merseburger A, Stenzl A, Steuber T, Suttmann H, Trojan L, Wirth M, Cerbone L, Conte P, Passalacqua R, Tucci M, Gerritsen W, Jassem J, Kalinka-Warzocha E, Olubiec J, De Bruyne R, Malan J, Vorobiof D, Bellmunt J, Carles J, Durán I, Font A, Gil-Bazo I, Maroto J, Bahl A, Choudhury A, Hoskin P, James N, Jones R, Mazhar D, O'Sullivan J, Payne H, Pedley I, Protheroe A, Waxman J, Zivi A, Alexander B, Appleman L, Aragon-Ching J, Arrowsmith E, Assikis V, Beer T, Berry W, Bolger G, Bryce A, Bubley G, Chatta G, Denmeade S, Deshpande H, Dorff T, Galsky M, George D, Giudice R, Glode M, Golshayan AR, Goodman O, Graff J, Green L, Green R, Haas N, Higano C, Hutson T, Kohli M, Liu G, May J, Mendelson D, Picus J, Pili R, Posadas E, Redfern C, Rettig M, Ryan C, Scholz M, Sharifi N, Sosman J, Srinivas S, Tagawa S, Twardowski P, Vaishampayan U, Wong YN.

Author information




Enzalutamide (formerly called MDV3100) targets multiple steps in the androgen-receptor-signaling pathway, the major driver of prostate-cancer growth. We aimed to evaluate whether enzalutamide prolongs survival in men with castration-resistant prostate cancer after chemotherapy.






Enzalutamide significantly prolonged the survival of men with metastatic castration-resistant prostate cancer after chemotherapy. (Funded by Medivation and Astellas Pharma Global Development; AFFIRM number, NCT00974311.).

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center